Recent News

• 03.03.2025 - Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules
• 03.03.2025 - Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules
• 03.03.2025 - Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules
• 03.03.2025 - Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules
• 02.19.2025 - Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
• 02.19.2025 - Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
• 02.19.2025 - Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
• 02.03.2025 - Akari Therapeutics Joins Webull Corporate Connect Service Platform
• 02.03.2025 - Akari Therapeutics Joins Webull Corporate Connect Service Platform
• 02.03.2025 - Akari Therapeutics Joins Webull Corporate Connect Service Platform

Recent Filings

• 02.14.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 02.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.07.2025 - 4/A Statement of changes in beneficial ownership of securities
• 01.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.13.2025 - 8-K Current report
• 01.13.2025 - EX-99.1 EX-99.1
• 01.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.07.2025 - 4 Statement of changes in beneficial ownership of securities